AustralianSuper Pty Ltd Has $49.93 Million Stock Position in AbbVie Inc. $ABBV

AustralianSuper Pty Ltd increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 2,717.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 215,623 shares of the company’s stock after purchasing an additional 207,971 shares during the quarter. AustralianSuper Pty Ltd’s holdings in AbbVie were worth $49,925,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of ABBV. Mirae Asset Global Investments Co. Ltd. boosted its holdings in AbbVie by 3.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 824,201 shares of the company’s stock valued at $190,836,000 after acquiring an additional 25,942 shares during the last quarter. Oxler Private Wealth LLC lifted its position in AbbVie by 0.4% during the 3rd quarter. Oxler Private Wealth LLC now owns 17,074 shares of the company’s stock valued at $3,953,000 after purchasing an additional 72 shares during the period. Mystic Asset Management Inc. lifted its position in AbbVie by 0.3% during the 3rd quarter. Mystic Asset Management Inc. now owns 20,933 shares of the company’s stock valued at $4,847,000 after purchasing an additional 54 shares during the period. RAM Investment Partners LLC boosted its stake in shares of AbbVie by 2.1% in the 3rd quarter. RAM Investment Partners LLC now owns 6,489 shares of the company’s stock valued at $1,502,000 after purchasing an additional 131 shares during the last quarter. Finally, Rockline Wealth Management LLC grew its position in shares of AbbVie by 0.3% during the 3rd quarter. Rockline Wealth Management LLC now owns 32,740 shares of the company’s stock worth $7,581,000 after buying an additional 103 shares during the period. Institutional investors own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Retrospective look: an analysis of why AbbVie outperformed in 2025 highlights management’s handling of blockbuster patent cliffs and portfolio transitions, supporting investor confidence in AbbVie’s strategy and cash returns. Why AbbVie Stock Trounced the Market in 2025
• Positive Sentiment: Berenberg raised its price target to $275 (from $270) and kept a Buy rating, citing momentum for Skyrizi and Rinvoq — a bullish signal from an institutional analyst that can support upside. Berenberg Grows More Confident in AbbVie
• Positive Sentiment: AbbVie and Novartis announced multi‑billion dollar licensing arrangements for oncology and Alzheimer’s treatments — a pipeline/collaboration boost that could add long-term revenue optionality. AbbVie and Novartis Announce Billion Dollar Licensing Deals
• Positive Sentiment: Clinical/dev updates: coverage discusses a bispecific trial win and AbbVie’s R&D commitments that could strengthen the growth narrative if results translate to approvals. Does AbbVie’s Bispecific Trial Win…
• Positive Sentiment: AbbVie completed a Phase 1 study for an on‑body injector to deliver risankizumab — operational progress that could improve dosing convenience and commercial uptake. AbbVie Advances Risankizumab Delivery
• Positive Sentiment: Allergan Aesthetics released pooled Phase 3 and Phase 4 data across injectables at IMCAS, underscoring strength in the aesthetics business line. Allergan Aesthetics Unveils New Data
• Positive Sentiment: On-air analyst support: a CNBC guest recommended staying long AbbVie, a short-term endorsement that can help sentiment. AbbVie on CNBC’s ‘Final Trades’
• Neutral Sentiment: Options activity: commentary notes unusual options movement, worth watching for short-term volatility but not definitive direction. Is the Options Market Predicting a Spike?
• Neutral Sentiment: Insider/holder note: a small asset manager disclosed a modest stake increase — a minor vote of confidence but immaterial to market cap. Belpointe Asset Management Increases Stake
• Neutral Sentiment: Corporate philanthropy: the AbbVie Foundation opened applications for a health equity accelerator — positive PR but unlikely to move the stock. AbbVie Foundation Health Equity Accelerator
• Negative Sentiment: Policy risk: CMS named several AbbVie drugs for the third cycle of Medicare Drug Price Negotiations — a direct potential headwind to pricing and margins if negotiations lower reimbursement. US Medicare names Eli Lilly, Pfizer and AbbVie drugs
• Negative Sentiment: Earnings outlook: a Zacks preview said AbbVie lacks the setup for a clear earnings beat next week — a factor that can pressure near-term multiple and stock momentum. AbbVie Reports Next Week
• Negative Sentiment: Analyst change: Citigroup trimmed its price target to $230 and moved to Neutral, signaling less near-term upside from analyst coverage. Citigroup Lowers Price Target

AbbVie Stock Down 2.2%

ABBV opened at $218.99 on Thursday. The stock has a market cap of $387.04 billion, a P/E ratio of 165.90, a P/E/G ratio of 0.92 and a beta of 0.36. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company has a fifty day simple moving average of $224.85 and a 200 day simple moving average of $218.01.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the previous year, the firm earned $3.00 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s dividend payout ratio is 524.24%.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a report on Tuesday, January 20th. UBS Group reiterated a “neutral” rating on shares of AbbVie in a research report on Tuesday, January 13th. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a research note on Wednesday. Morgan Stanley lifted their price objective on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $249.37.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.